

# List of Figures and Tables

1.01   p. 50	□	Global Pharmaceutical Sales, 2001-2007
1.02   p. 50	□	Major World Markets: Population Size and Sales Growth
1.03   p. 51	□	Global Pharma Sales by Region: 2005-2006
1.04   p. 51	□	Pharmaceutical Sales by Region: Share of Worldwide Market
1.05   p. 52	□	Global Pharma Sales Growth by Region
1.06   p. 52	□	Top 10 Pharma Markets: 2003, 2007, 2011
1.07   p. 53	□	Ten Fastest Growing Pharmaceutical Markets: 2004-2005
1.08   p. 53	□	Ethical Pharmaceutical Sales: Selected Emerging Markets
1.09   p. 54	□	Ethical Pharmaceutical Sales: Total PhRMA-member Company Sales, 2001-2007
1.10   p. 54	□	Ethical Pharmaceutical Sales: Total PhRMA-member Company Sales, 1997-2007
1.11   p. 55	□	Ethical Pharmaceutical Sales: Growth Rate, 2000-2007
1.12   p. 55	□	National Health Expenditures and Their Share of Gross Domestic Product: 2003-2017 (Projected)
1.13   p. 56	□	U.S. Pharmaceutical Spending Growth vs. Total Healthcare Spending Growth: 2003-2017
1.14   p. 56	□	Growth in Prescription Drug Spending: 1988-2015
1.15   p. 57	□	Overall Consumer Price Index (CPI) and Medical-specific Consumer Price Index (MCPI): 1993-2008
1.16   p. 57	□	2006 Major European Pharmaceutical Sales
1.17   p. 58	□	Pharmaceutical Market in Canada: 2003-2007
1.18   p. 58	□	2006 Pharmaceutical Market in Latin America
1.19   p. 59	□	2005 Pharmaceutical and Medicine Manufacturing in Africa

1.20   p. 59	<input type="checkbox"/>	Top 10 Pharmaceutical Companies: 2008 Pharmaceutical Revenues
1.21   p. 60	<input type="checkbox"/>	Top 10 Biotechnology Companies: 2008 Revenue
1.22   p. 60	<input type="checkbox"/>	Worldwide Prescription Sales by Technology: 2000-2012
1.23   p. 61	<input type="checkbox"/>	Worldwide Ethical Pharmaceutical Sales: Top Therapeutic Classes, 2006
1.24   p. 61	<input type="checkbox"/>	2007 Top 10 Worldwide Drug Sales
1.25   p. 62	<input type="checkbox"/>	2007 Top 10 Orphan Drug Sales
1.26   p. 62	<input type="checkbox"/>	Global Oncology Sales Estimate: 2003-2012
1.27   p. 63	<input type="checkbox"/>	2007 Biologics Sales by Region
1.28   p. 63	<input type="checkbox"/>	2007 Biologics Sales by Company
1.29   p. 64	<input type="checkbox"/>	2007 Biologics Sales by Therapy Classes
1.30   p. 64	<input type="checkbox"/>	2007 Biologics Sales Top Products
1.31   p. 65	<input type="checkbox"/>	Worldwide Medical Device Market: Projected Sales Through 2009
1.32   p. 65	<input type="checkbox"/>	U.S. Medical Device Market: Projected Sales 2004-2009
1.33   p. 66	<input type="checkbox"/>	Worldwide Medical Device Sales: 2004 Estimated Market Share by Region
1.34   p. 66	<input type="checkbox"/>	Medical Device Market: Largest Treatment Areas by Total Sales, 2003
1.35   p. 67	<input type="checkbox"/>	Select Medical Device Manufacturers: Total Device Revenues, 2008
1.36   p. 67	<input type="checkbox"/>	Medical Devices: Worldwide and U.S. Revenues
1.37   p. 68	<input type="checkbox"/>	Generic Pharmaceutical Market: Total Worldwide Sales, 1998-2003
1.38   p. 68	<input type="checkbox"/>	Generic Pharmaceutical Market: Total U.S. Sales, 2002-2007
1.39   p. 69	<input type="checkbox"/>	Top 10 Generic Companies: 2008 Revenue
1.40   p. 69	<input type="checkbox"/>	Top 10 Generic Molecules by 2007 Sales
1.41   p. 70	<input type="checkbox"/>	Generics Percentage of Total Prescriptions Filled
1.42   p. 70	<input type="checkbox"/>	U.S. Prescriptions: 2002-2007
1.43   p. 71	<input type="checkbox"/>	Generic Share of Prescriptions: 1998-2005
1.44   p. 71	<input type="checkbox"/>	Generic Substitution Rates: Select Countries
1.45   p. 72	<input type="checkbox"/>	Sales Vulnerable to Generic Competition: Selected Top Companies Through 2012
1.46   p. 72	<input type="checkbox"/>	Top Drugs Facing Generic Competition: U.S. Patent Expiration by Year
1.47   p. 73	<input type="checkbox"/>	Market Share Lost 12 Months After Patent Expiration

2.01   p. 86	□	Projected R&D Spending: Pharmaceutical and Biotech Companies, 2006-2011
2.02   p. 86	□	R&D Spending Growth Rates: PhRMA-member Companies, 1980-2005
2.03   p. 87	□	A New Wave of Pipeline Growth: Projects Worldwide (Discovery – Clinical)
2.04   p. 87	□	NME Approval and Domestic R&D Expenditure: 1997-2007
2.05   p. 88	□	World R&D Market Share: PhRMA-member Companies
2.06   p. 88	□	Domestic R&D Spending: PhRMA-member Companies, 1998-2007
2.07   p. 89	□	R&D Spending Abroad: PhRMA-member Companies, 1998-2007
2.08   p. 89	□	Top 10 Pharmaceutical Companies by R&D Spending: 2008
2.09   p. 90	□	Top 10 Biotechnology Companies by R&D Spending: 2008
2.10   p. 90	□	R&D Spending as a Percent of Sales: PhRMA-member Companies
2.11   p. 91	□	R&D Spending as a Percent of Sales: Distribution by Industry Type, 2009E
2.12   p. 91	□	Projected Pharma R&D as a Percent of Sales: Worldwide Spending, 2006-2011
2.13   p. 92	□	The Cost of Developing a Single Drug: Total Capitalized Costs, in Constant 2005 Dollars
2.14   p. 92	□	Costs per Approved Biopharmaceutical
2.15   p. 93	□	Total Spending on Clinical Collaborations: PhRMA-member Companies
2.16   p. 93	□	PhRMA-member R&D Spending: Expenditure by Function, 2006
2.17   p. 94	□	Clinical Development: Total PhRMA-member Spending in the U.S., by Phase
2.18   p. 94	□	Spending on Development: Projected Spending, by Phase
2.19   p. 95	□	Spending on Development: Projected Spending 2008-2012
2.20   p. 95	□	Spending on Phase IV Trials: PhRMA-member Companies
2.21   p. 96	□	Distribution of R&D: Funding by Therapeutic Area, 2004
2.22   p. 96	□	Distribution of R&D: Percentage of Total Funding Across Top Therapeutic Areas, 1999-2007
2.23   p. 97	□	Pharmaceutical R&D: Funding by Therapeutic Area, 1999-2007
2.24   p. 97	□	Sources of Trial Funding
2.25   p. 98	□	Industry and Government Sponsored R&D Expenditure, 2004-2007
2.26   p. 98	□	Sponsorship of Trials: Type of Sponsor, All Phases
2.27   p. 99	□	Sponsorship of Phase II Trials: Type of Sponsor

2.28   p. 99	□	Sponsorship of Phase III Trials: Type of Sponsor
2.29   p. 100	□	Sponsorship of Phase IV Trials: Type of Sponsor
2.30   p. 100	□	Industry Sponsorship of Trials: Top Countries with Industry Sponsorship, All trials
2.31   p. 101	□	Industry Sponsorship of Phase II Trials: Top Countries with Industry Sponsorship
2.32   p. 101	□	Industry Sponsorship of Phase III Trials: Top Countries with Industry Sponsorship
2.33   p. 102	□	Industry Sponsorship of Phase IV Trials: Top Countries with Industry Sponsorship
2.34   p. 102	□	Total NIH Grants: Grants to All Research Interests, 1999-2007
2.35   p. 103	□	NIH Grants to Foreign Countries: Grants to All Research Interests, 2000-2008
2.36   p. 103	□	International NIH Grant Recipients: Top Recipients by Country, 2008
2.37   p. 104	□	NIH Sponsorship of Trials: Top Countries with NIH Sponsorship, All trials
2.38   p. 104	□	NIH Sponsorship of Phase II Trials: Top Countries with NIH Sponsorship
2.39   p. 105	□	NIH Sponsorship of Phase III Trials: Top Countries with NIH Sponsorship
2.40   p. 105	□	NIH Sponsorship of Phase IV Trials: Top Countries with NIH Sponsorship
2.41   p. 106	□	NIH Grants by Disease: Estimated Distribution of Funding by Therapeutic Area, 2008
2.42   p. 106	□	Federally Funded Clinical Research: Distribution of 2007 Funding by Source
2.43   p. 107	□	New NIH Grants: Type I Research Project Grants, 1998-2007
2.44   p. 107	□	NIH Funding by Region: Top 10 States and International by Total Grant Amount, 2007
2.45   p. 108	□	NIH Funding per Capita: Top 10 States, 2007
3.01   p. 118	□	Clinical Trial Initiations: Based in FDA-1572, 1990-2007
3.02   p. 118	□	Worldwide Clinical Trials: Estimated Ongoing Phase I-III Trials, 2000-2006
3.03   p. 119	□	A New Wave of Pipeline Growth: Projects Worldwide (Discovery – Clinical)

3.04   p. 119	□	Distribution of Clinical Development: Active Projects by Phase, as of December 2008
3.05   p. 120	□	Clinical Trials per NDA: Mean Number of Trials in Drugs Reaching Approval by Phase
3.06   p. 120	□	NMEs/BLAs Submitted to the FDA by Year
3.07   p. 121	□	The Clinical Development Cycle
3.08   p. 121	□	The Pharmaceutical Development Cycle: Total Cycle Time: 20 Years
3.09   p. 122	□	Chance of IND-accepted Drug Entering a Development Phase
3.10   p. 122	□	Chance of Drug Completing Each Development Phase
3.11   p. 123	□	NCE Approval Success Rates by Therapeutic Class
3.12   p. 123	□	Sponsor Development Time Goals
3.13   p. 124	□	Causes of Study Initiation Delays in the United States
3.14   p. 124	□	Causes of Study Initiation Delays in Europe
3.15   p. 125	□	Enrollment Delays in the United States: Distribution of Delays in Site Enrollment Timeliness
3.16   p. 125	□	Enrollment Delays: Distribution of Delays in Site Enrollment Timeliness
3.17   p. 126	□	Drugs in Development by Therapeutic Area: Total Active INDs at Year-end 2007 for Top Categories
3.18   p. 126	□	Therapeutic Area Growth: Growth in Number of Active INDs, 2006-2007
3.19   p. 127	□	Number of Active INDs at Year-end, 2006
3.20   p. 127	□	Distribution of Commercial and Non-commercial INDs, 2006
3.21   p. 128	□	Top Six Pharmaceutical Pipelines: Total Drugs in Development, Including Collaborations, 2008
3.22   p. 128	□	R&D Pipelines of Top Companies: Number of Total Drugs in Development, 15 Largest Pipelines
3.23   p. 129	□	R&D Pipelines of Top Companies: Number of Own-drugs in Development, 15 Largest Pipelines
3.24   p. 129	□	Top Countries in Trials: Most Listed Companies
3.25   p. 130	□	Licensing Among Top 10 Pharmas
3.26   p. 130	□	The Potential Cost of Delays: Worldwide Sales for the Top Five Blockbuster Drugs, 2007
3.27   p. 131	□	Comparing Development Times: Mean Time from First Synthesis to Approval for NMEs Approved, 2001
3.28   p. 131	□	Clinical and Approval Times: Total Time, 2000-2006

- 3.29 | p. 132 □ Comparing Cycle Times by NCE Type: Average Time in Years
- 3.30 | p. 132 □ Average Clinical Development Time: Median Total Time from IND to Approval
- 3.31 | p. 133 □ Average Cost of One Day of Clinical Development, 2005
- 3.32 | p. 133 □ Mean Exclusivity for First-in-class Approvals
- 3.33 | p. 134 □ Average Clinical Development Time: Mean Total Time by Therapeutic Area and Phase
- 3.34 | p. 134 □ Average Clinical Development Time: Mean Total Time by Therapeutic Area and Phase, Successful Trials
- 3.35 | p. 135 □ Average Clinical Development Time: Mean Total Time by Therapeutic Area and Phase, Unsuccessful Trials
- 3.36 | p. 135 □ Average Clinical Development Time: Mean Total Time by Company Size and Phase, all TAs
- 3.37 | p. 136 □ Time to Completing Phase for Successful and Failed Trials
- 3.38 | p. 136 □ Increases in Phase I Spending Improve Phase III Success
- 3.39 | p. 137 □ Scope of Clinical Projects: Mean Number of Subjects and Sites per Trial
- 3.40 | p. 137 □ Differences in Phase I Trials: Index of Number of Subjects in Phase I Trials for Selected TAs
- 3.41 | p. 138 □ Differences in Phase I Trials: Index of Number of Sites in Phase I Trials for Selected TAs
- 3.42 | p. 138 □ Differences in Phase II Trials: Index of Number of Subjects in Phase II Trials for Selected TAs
- 3.43 | p. 139 □ Differences in Phase II Trials: Index of Number of Sites in Phase II Trials for Selected TAs
- 3.44 | p. 139 □ Differences in Phase III Trials: Index of Number of Subjects in Phase III Trials for Selected TAs
- 3.45 | p. 140 □ Differences in Phase III Trials: Index of Number of Sites in Phase III Trials for Selected TAs
- 3.46 | p. 140 □ Trials by Phase in Russia: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.47 | p. 141 □ Trials by Phase in Australia: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.48 | p. 141 □ Trials by Phase in China: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.49 | p. 142 □ Trials by Phase in India: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.50 | p. 142 □ Trials by Phase in France: Drug and Biological Trials Listed on Clinicaltrials.gov

- 3.51 | p. 143 | □ Trials by Phase in Poland: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.52 | p. 143 | □ Trials by Phase in Spain: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.53 | p. 144 | □ Trials by Phase in the United Kingdom: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.54 | p. 144 | □ Trials by Phase in Germany: Drug and Biological Trials Listed on Clinicaltrials.gov
- 3.55 | p. 145 | □ Rising Project Complexity: Mean Number of Procedures per Patient, 1996-2005
- 3.56 | p. 145 | □ Rising Project Complexity: Mean Number of Procedures per Patient by Phase, 2001-2006
- 3.57 | p. 146 | □ Clinical Trial Complexity by Trial Phase: U.S., Western Europe, Eastern Europe, Asia, 2005-2007
- 3.58 | p. 146 | □ Index of Cost of Conducting Trials: Select Countries, 2007
- 3.59 | p. 147 | □ Cost of U.S. Clinical Trials: Mean Cost per Patient, by Phase, 2001-2006
- 3.60 | p. 147 | □ Cost of U.S. Clinical Trials: Median Cost per Patient, by Therapeutic Area, 2001-2006
- 3.61 | p. 148 | □ Mean Cost per Patient in Clinical Trials: U.S., Western Europe, Eastern Europe, Asia, 2005-2007
- 3.62 | p. 148 | □ Mean Cost per Patient by Therapeutic Area: U.S., Western Europe, Eastern Europe, Asia, 2005-2007
- 3.63 | p. 149 | □ Mean Cost per Patient by Therapeutic Area: U.S., Western Europe, Eastern Europe, Asia, 2005-2007
- 3.64 | p. 149 | □ Sample Patient Reduction from Adaptive Trial Approach
- 3.65 | p. 150 | □ Drugs in Pediatric Trials: Distribution of Projects by Phase
- 3.66 | p. 150 | □ Drugs in Pediatric Trials: Distribution of Projects by Phase, 2008
- 3.67 | p. 151 | □ Top Five Therapeutic Areas in Pediatric Development
- 3.68 | p. 151 | □ Top Five Sponsors Conducting Pediatric Trials by Number of Pediatric Development Projects
- 3.69 | p. 152 | □ Grants of Pediatric Exclusivity by Company
- 3.70 | p. 152 | □ Grants of Pediatric Exclusivity by Type
- 3.71 | p. 153 | □ Written Requests for Pediatric Exclusivity
- 3.72 | p. 153 | □ Written Requests by FDA Review Division
- 3.73 | p. 154 | □ Proposed Pediatric Study Requests by FDA Review Division

3.74   p. 154	<input type="checkbox"/>	Studies Requested, Pediatric: Patients Needed
3.75   p. 155	<input type="checkbox"/>	Post-marketing Commitments: Pediatric Components
5.01   p. 232	<input type="checkbox"/>	Factors Most Often Causing Study Delays in the United States
5.02   p. 232	<input type="checkbox"/>	Factors Most Often Causing Study Delays in Europe
5.03   p. 233	<input type="checkbox"/>	Factors Most Often Causing Study Delays in Asia-Pacific
5.04   p. 233	<input type="checkbox"/>	Enrollment Delays: Distribution of Delays in Site Enrollment Timeliness
5.05   p. 234	<input type="checkbox"/>	Enrollment Delays in the United States
5.06   p. 234	<input type="checkbox"/>	Enrollment Delays in Europe
5.07   p. 235	<input type="checkbox"/>	Factors That Could Best Prevent Future Delays in the United States
5.08   p. 235	<input type="checkbox"/>	Factors That Could Best Prevent Future Delays in Europe
5.09   p. 236	<input type="checkbox"/>	Factors That Could Best Prevent Future Delays in Asia-Pacific
5.10   p. 236	<input type="checkbox"/>	EDC as a Factor That Could Best Prevent Future Delays
5.11   p. 237	<input type="checkbox"/>	Factors That can Best Prevent Future Study Delays
5.12   p. 237	<input type="checkbox"/>	Factors That Could Best Prevent Future Delays
5.13   p. 238	<input type="checkbox"/>	How Has Sponsor Performance in the United States Changed in the Past Three Years With Regards to:
5.14   p. 238	<input type="checkbox"/>	How Has Sponsor Performance in Europe Changed in Past Three Years with Regards to:
5.15   p. 239	<input type="checkbox"/>	How Has Sponsor Performance in Asia Pacific Changed in Past Three Years with Regards to:
5.16   p. 239	<input type="checkbox"/>	Average Rating for the Typical Sponsor in the United States
5.17   p. 240	<input type="checkbox"/>	Average Rating for the Typical Sponsor in Europe
5.18   p. 240	<input type="checkbox"/>	Top Rated Sponsors in the United States
5.19   p. 241	<input type="checkbox"/>	Top Rated Sponsors in Europe
5.20   p. 241	<input type="checkbox"/>	Highest Frequency as a Top Three Rated Sponsor Across 27 Relationship Attributes in the United States
5.21   p. 242	<input type="checkbox"/>	Highest Frequency as a Top Three Rated Sponsor Across 28 Relationship Attributes in Europe
5.22   p. 242	<input type="checkbox"/>	Quality of General Project Management in the United States
5.23   p. 243	<input type="checkbox"/>	Quality of General Project Management in Europe
5.24   p. 243	<input type="checkbox"/>	Quality of the Study Initiation Process in the United States
5.25   p. 244	<input type="checkbox"/>	Quality of the Study Initiation Process in Europe

5.26   p. 244	□	Quality of the Grant Payment Process in the United States
5.27   p. 245	□	Quality of the Grant Payment Process in Europe
5.28   p. 245	□	Quality of Staff Professionalism in the United States
5.29   p. 246	□	Quality of Staff Professionalism in Europe
5.30   p. 246	□	Quality of Workstyle in the United States
5.31   p. 247	□	Quality of Workstyle in Europe
5.32   p. 247	□	Quality of Ongoing Study Support in the United States
5.33   p. 248	□	Quality of Ongoing Study Support in Europe
5.34   p. 248	□	General Project Management Evaluated in the United States
5.35   p. 249	□	Project Attributes Evaluated in the United States
5.36   p. 249	□	Project Attributes Evaluated in the United States
5.37   p. 250	□	Personnel and Work Style Evaluated in the United States
5.38   p. 250	□	Relationship Attributes Evaluated in Europe
5.39   p. 251	□	Relationship Attributes Evaluated in Europe
5.40   p. 251	□	Relationship Attributes Evaluated in Europe
5.41   p. 252	□	Relationship Attributes Evaluated in Europe
5.42   p. 252	□	Comparing Performance Quality with Category Importance in the United States
5.43   p. 253	□	Comparing Performance Quality with Category Importance in Europe
5.44   p. 253	□	Essential Attributes to Study Success in the United States
5.45   p. 254	□	Essential Attributes to Study Success in Europe
5.46   p. 254	□	Essential Attributes to Study Success in Latin America
5.47   p. 255	□	Small Company Layoff Announcements: January 2008 to January 2009
5.48   p. 255	□	Small Company Layoff Announcements: by Percentage of Staff Reduction
5.49   p. 256	□	Small Company Layoff Announcements Cost and Savings Estimates
6.01   p. 268	□	Worldwide CRO Market: CRO Market Size and Growth Rate, 2007-2012
6.02   p. 268	□	Number of Clinical CROs in Europe and North America
6.03   p. 269	□	Shifting Share of Clinical Projects: Share of Industry-sponsored Projects

6.04   p. 269	□	Pharmaceutical R&D Spending: Outsourced R&D Growth Outpacing Growth in Total R&D
6.05   p. 270	□	CRO Involvement
6.06   p. 270	□	Use of CRO Services: Sponsors' Reasons for Outsourcing Trial Efforts
6.07   p. 271	□	Top Niche CRO Services Utilized
6.08   p. 271	□	Top Niche CRO Services Utilized: 2003 and 2005
6.09   p. 272	□	CRO Usage in Phase I - III Projects: Percent of Clinical Projects Where CRO Played Significant Role
6.10   p. 272	□	Top Public CRO Companies: 2008 Revenues
6.11   p. 273	□	Select CRO Share Prices: Compared with Major Indices
6.12   p. 273	□	CRO Acquisitions: Total Acquisitions of Clinical CROs, 1998-2008
6.13   p. 274	□	Select 2006 CRO Acquisitions of Phase I Operations
6.14   p. 274	□	Select 2005 CRO Acquisitions
6.15   p. 275	□	Select 2006 CRO Acquisitions: Part 1
6.16   p. 275	□	Select 2006 CRO Acquisitions: Part 2
6.17   p. 276	□	Estimated Revenue Matrix: Select Public CROs
6.18   p. 276	□	Sites Rating CRO Services "Very Important" and "Excellent"
6.19   p. 277	□	Attributes More Important for CROs Than Sponsors in Europe
6.20   p. 277	□	Attributes More Important for CROs Than Sponsors in the United States
6.21   p. 278	□	CRO Performance in the United States
6.22   p. 278	□	CRO Performance in Europe
6.23   p. 279	□	Comparing CRO Performance Quality with Category Importance in the United States
6.24   p. 279	□	Comparing CRO Performance Quality with Category Importance in Europe
6.25   p. 280	□	Top CROs in the United States
6.26   p. 280	□	Highest Frequency as a Top Three Rated CRO in the United States Across 29 Relationship Attributes
6.27   p. 281	□	CRO Project Management in the United States
6.28   p. 281	□	CRO Professionalism and Work Style in the United States
6.29   p. 282	□	CRO Project Initiation and Grant Payment in the United States
6.30   p. 282	□	CRO Ongoing Study Conduct in the United States
6.31   p. 283	□	CRO Project Management in Europe

6.32   p. 283	□	CRO Professionalism and Work Style in Europe
6.33   p. 284	□	CRO Project Initiation and Grant Payment in Europe
6.34   p. 284	□	CRO Ongoing Study Conduct in Europe
6.35   p. 285	□	CRO Performance in the United States
6.36   p. 285	□	CRO Performance in Europe
6.37   p. 286	□	Top Rated CROs in the United States: Select Project Attributes
6.38   p. 286	□	SMO Market Size: Worldwide Total Sales of SMO Services, 1996-2004
6.39   p. 287	□	SMOs in Clinical Trials: Reported Annual Growth in Clinical Trials Conducted by SMOs
6.40   p. 287	□	Number of SMOs: Worldwide Totals by Region, 2006
6.41   p. 288	□	SMO Company Size: Distribution of SMOs by Number of Investigators
6.42   p. 288	□	SMO Company Size: Distribution of SMOs by Number of Sites
7.01   p. 298	□	Pharmaceutical Outsourcing Penetration
7.02   p. 298	□	Outsourcing Expenditure: Percentage of R&D Expenditure Outsourced
7.03   p. 299	□	Trial Outsourcing Distribution: Outsourced Trials by Provider Type, 2006
7.04   p. 299	□	Biotech Infrastructure Expenditure: Spend on Technology, 2005
7.05   p. 300	□	Summary of Outsourcing Department Functions
7.06   p. 300	□	Distribution of Services Provided by Outsourcing Departments
7.07   p. 301	□	Top Services Provided by Outsourcing Departments
7.08   p. 301	□	Primary Department Responsibilities
7.09   p. 302	□	Primary Department Responsibilities, 2003 and 2005
7.10   p. 302	□	Top Regions Handled by Outsourcing Departments
7.11   p. 303	□	Highest Degree Attained by Outsourcing Department Personnel
7.12   p. 303	□	Outsourcing Department Reporting Structure
7.13   p. 304	□	Outsourcing Department Staffing Profile
7.14   p. 304	□	Changes in Outsourcing Department Headcount: During Previous 12-18 Months
7.15   p. 305	□	Location of Outsourcing Department Personnel
7.16   p. 305	□	Staff Workload
7.17   p. 306	□	How Department is Initially Engaged

7.18   p. 306	<input type="checkbox"/>	Top Three Department Responsibilities
7.19   p. 307	<input type="checkbox"/>	Criteria Used to Measure Outsourcing Department Effectiveness
7.20   p. 307	<input type="checkbox"/>	Department Impact on Clinical Projects Last Year
7.21   p. 308	<input type="checkbox"/>	Impact on Clinical Projects: 2003 and 2005
7.22   p. 308	<input type="checkbox"/>	Frequency of Preparing Justification
7.23   p. 309	<input type="checkbox"/>	Ideal Metrics Departments are Looking to Achieve
7.24   p. 309	<input type="checkbox"/>	Ideal Metrics Comparisons: 2003 and 2005
7.25   p. 310	<input type="checkbox"/>	Types of Contracts Responsible for:
7.26   p. 310	<input type="checkbox"/>	Top Factors Rated Important when Selecting a Vendor
7.27   p. 311	<input type="checkbox"/>	Importance of Vendor: Selection Criteria
7.28   p. 311	<input type="checkbox"/>	Full-service and Niche Vendor: Selection Criteria
7.29   p. 312	<input type="checkbox"/>	Outsourcing Strategies Pursued
7.30   p. 312	<input type="checkbox"/>	Contract Pricing Structures
7.31   p. 313	<input type="checkbox"/>	Financial Incentives Utilized
7.32   p. 313	<input type="checkbox"/>	Financial Penalties Utilized
7.33   p. 314	<input type="checkbox"/>	Top Project Payment Schedule Structures
7.34   p. 314	<input type="checkbox"/>	Project Payment Schedule: Structures Utilized
7.35   p. 315	<input type="checkbox"/>	CRO Performance Metrics Gathered
7.36   p. 315	<input type="checkbox"/>	Top Methods of Communication
7.37   p. 316	<input type="checkbox"/>	Methods of Communication Utilized
7.38   p. 316	<input type="checkbox"/>	Total Active U.S. IRBs
7.39   p. 317	<input type="checkbox"/>	OHRP-registered IRBs
7.40   p. 317	<input type="checkbox"/>	IRBs by Location: States with the Highest Number of Active IRBs
7.41   p. 318	<input type="checkbox"/>	EDC Solutions: Estimated Market Size, 2004-2010
7.42   p. 318	<input type="checkbox"/>	What is the Percentage of Trials at Your Site That Uses EDC?
7.43   p. 319	<input type="checkbox"/>	In What Year Were You First Required to Use EDC?
7.44   p. 319	<input type="checkbox"/>	How Many Companies Have Trained You on EDC?
7.45   p. 320	<input type="checkbox"/>	What Type of EDC Have You Used at Your Site?
7.46   p. 320	<input type="checkbox"/>	What Type of Company Has Trained You on EDC?
7.47   p. 321	<input type="checkbox"/>	Has the Effectiveness of Your EDC Training Over the Course of Your Career:
7.48   p. 321	<input type="checkbox"/>	Paper vs. EDC Cost Comparison

- 7.49 | p. 322 □ Clinical Trial Laboratory Services: Total Sales, 2004-2012
- 7.50 | p. 322 □ Clinical Trial Laboratory Services Market Share: Total Market = \$1.6 Billion in 2005
- 7.51 | p. 323 □ Which Statement Best Describes the Type of Electronic Medical Record That You use?
- 7.52 | p. 323 □ Estimated EHR Market Growth: 2005-2015
- 7.53 | p. 324 □ EHR Uptake by Practice Size
- 7.54 | p. 324 □ Top Five Benefits of EHR
- 7.55 | p. 325 □ Top Five Barriers to Implementing EHR
- 7.56 | p. 325 □ Patient Experience with New Medical Technologies
- 7.57 | p. 326 □ Select EHR Providers
- 7.58 | p. 326 □ Molecular Imaging Market: Various Techniques
- 7.59 | p. 327 □ Molecular Imaging Market: Estimated Total Sales 2004-2009
- 7.60 | p. 327 □ E-Diaries Market Estimate
- 7.61 | p. 328 □ E-Diaries Uptake Estimate
- 7.62 | p. 328 □ Technologies to Capture Clinical E-Diary Data: Phases I-III
- 7.63 | p. 329 □ Compliance: Paper vs. E-Diaries
- 7.64 | p. 329 □ Increased Compliance=Increased Quality of Results=Easier Trial Conduct
- 7.65 | p. 330 □ E-Diaries Major Players
- 
- 8.01 | p. 340 □ Clinical Investigators: Number of Investigators Submitting INDs
- 8.02 | p. 340 □ Clinical Investigators: U.S. vs. Non-U.S. Investigators Submitting INDs
- 8.03 | p. 341 □ New Studies and New Investigators: All U.S. INDs
- 8.04 | p. 341 □ New Studies and New Investigators: All U.S. Investigators
- 8.05 | p. 342 □ New Studies and New Investigators: Non-U.S. Investigators
- 8.06 | p. 342 □ First-time Investigators: 1980-2007
- 8.07 | p. 343 □ First-time Investigators by Origin, 1980-2007
- 8.08 | p. 343 □ Investigators Filing One Form 1572 Only
- 8.09 | p. 344 □ Profile of Investigators Filing FDA-1572
- 8.10 | p. 344 □ Physicians Participating in Clinical Trials: Percentage of Surveyed Physicians with Clinical Trial Experience
- 8.11 | p. 345 □ Number of Trials Participated in

- 8.12 | p. 345 □ Physician Inclination to Participate in Another Trial
- 8.13 | p. 346 □ Why or Why Not Participate: Never Participated
- 8.14 | p. 346 □ Why or Why Not Participate Again: Have Participated
- 8.15 | p. 347 □ Referring Patients into Alternate Investigator's Clinical Trials
- 8.16 | p. 347 □ Referring Patients into Alternate Investigator's Clinical Trials: Prior vs. Non-prior
- 8.17 | p. 348 □ Reasons Physicians Don't Refer Patients into Trials: All
- 8.18 | p. 348 □ Reasons Physicians Don't Refer Patients into Trials: Prior
- 8.19 | p. 349 □ Reasons Physicians Don't Refer Patients into Trials: Non-prior
- 8.20 | p. 349 □ What Would Increase Level of Comfort to Refer Patients: Prior
- 8.21 | p. 350 □ What Would Increase Level of Comfort to Refer Patients: Non-prior
- 8.22 | p. 350 □ R&D Personnel
- 8.23 | p. 351 □ Number of People Employed in Health Care: 1991-2005
- 8.24 | p. 351 □ Clinical Research Personnel: Distribution of Personnel by Specialty, 2006
- 8.25 | p. 352 □ U.S. Clinical Research Professionals: Total Number of Clinical Researchers by Employment Type
- 8.26 | p. 352 □ U.S. Investigator Profile: Most Are Full-time Researchers
- 8.27 | p. 353 □ European Investigator Profile: Most Are Part-time Researchers
- 8.28 | p. 353 □ Latin American Investigator Profile: Most Are Part-time Researchers
- 8.29 | p. 354 □ Aging Investigators: NIH Traditional Grant Recipients by Age, 1980-2006
- 8.30 | p. 354 □ Medical School Graduates by Race and Ethnicity: 1980-2004
- 8.31 | p. 355 □ European Study Coordinators: Percentage of Sites Employing a Study Coordinator
- 8.32 | p. 355 □ Investigator Productivity: Number of Studies Conducted per Investigator
- 8.33 | p. 356 □ Comparing Productivity: Average Number of Industry-sponsored Trials Conducted per Position
- 8.34 | p. 356 □ Comparing Productivity: Average Number of Industry-sponsored Trials Conducted per Position
- 8.35 | p. 357 □ Full-time Coordinators: Distribution of Sites by Number of Full-time CRCs
- 8.36 | p. 357 □ CRC Productivity: 2001 vs. 2009
- 8.37 | p. 358 □ Distribution of Full-time Coordinators

8.38   p. 358	□	Distribution of Part-time Coordinators
8.39   p. 359	□	Patient Recruitment Specialist Distribution
8.40   p. 359	□	Patient Recruitment Specialists
8.41   p. 360	□	A Need for More Clinical Investigator Training
8.42   p. 360	□	Primary Training Sources for Investigators
8.43   p. 361	□	Industry Grants per Trial: 2002-2007
8.44   p. 361	□	Selecting Countries for Multinational Trials: Key Criteria Used by Sponsors
8.45   p. 362	□	Investigative Site Operating Concerns: Most Frequent Responses
8.46   p. 362	□	What Is the Biggest Challenge You Face Today?
8.47   p. 363	□	Investigative Site Perceptions of Changes in Profit per Grant
8.48   p. 363	□	Sponsor and CRO Payment Tardiness: Site Perceptions of Changes in Payment Timeliness
8.49   p. 364	□	Reported Operating Margins: Average Across Investigative Sites
8.50   p. 364	□	Real Fees per Patient: Average Fees Paid U.S. vs. E.U.
8.51   p. 365	□	Average Site Expenditures
8.52   p. 365	□	Typical Investigative Site Revenue Allocation: 2007
8.53   p. 366	□	Grants vs. Volume
8.54   p. 366	□	Types of Trials Paying Subjects
8.55   p. 367	□	Phases of Trials Paying Subjects
8.56   p. 367	□	Payment Based on Size of Trial
8.57   p. 368	□	Was Payment Prorated?
8.58   p. 368	□	Institutional Policy Regarding Payment
8.59   p. 369	□	Factors Influencing Decision Not to Pay Subjects
8.60   p. 369	□	Factors Influencing Amounts of Payments Offered
8.61   p. 370	□	Would Recruitment Have Been Easier with Payment?
8.62   p. 370	□	Recruitment Would Have Been Easier if They Had Offered More Payment
8.63   p. 371	□	Biggest Challenges to Conducting Clinical Trials in Latin America
8.64   p. 371	□	Study Conduct in Latin America
8.65   p. 372	□	Training in Latin America
8.66   p. 372	□	Who Provided Training? Latin America
8.67   p. 373	□	Meeting Type Preference

8.68   p. 373	<input type="checkbox"/>	Live Meetings
8.69   p. 374	<input type="checkbox"/>	Most Valuable at Meetings
8.70   p. 374	<input type="checkbox"/>	Least Valuable at Meetings
8.71   p. 375	<input type="checkbox"/>	Do You Typically Attend the Study-Start up Meeting?
8.72   p. 375	<input type="checkbox"/>	Protocol Training
8.73   p. 376	<input type="checkbox"/>	Preferred Learning Methods
8.74   p. 376	<input type="checkbox"/>	Remote Meetings: Positives
8.75   p. 377	<input type="checkbox"/>	Remote Meetings: Negatives
8.76   p. 377	<input type="checkbox"/>	Who Attends Investigator Meetings?
8.77   p. 378	<input type="checkbox"/>	Novel Approaches to Investigator Meetings
8.78   p. 378	<input type="checkbox"/>	Percent Receiving Formal Training in Clinical Trials: Based on Number of Trials Participated in
8.79   p. 379	<input type="checkbox"/>	What Type of Training Did You Receive?
8.80   p. 379	<input type="checkbox"/>	Was the Training Adequate?
8.81   p. 380	<input type="checkbox"/>	What Factor Would Have the Most Impact on Your Decision to Leave Your Current job?
8.82   p. 380	<input type="checkbox"/>	What Other Type of Training do You Feel is Essential to Do Your Job?
8.83   p. 381	<input type="checkbox"/>	What is the Top Factor That Contributes to Delays in the Conduct of Your Trials at Your Site?
9.01   p. 392	<input type="checkbox"/>	Average Number of Evaluable Patients per NDA
9.02   p. 392	<input type="checkbox"/>	2003 Clinical Trial Participation by Country
9.03   p. 393	<input type="checkbox"/>	Frequency of Online Health Searches in the Last Month
9.04   p. 393	<input type="checkbox"/>	How U.S. Patients Learn About Trials
9.05   p. 394	<input type="checkbox"/>	Individuals Using the Internet to Find Health-related Information
9.06   p. 394	<input type="checkbox"/>	World Internet Penetration Rates
9.07   p. 395	<input type="checkbox"/>	Types of Online Health Information Portals Used by Patients
9.08   p. 395	<input type="checkbox"/>	Trial Information Distribution: Helping Patients Understand Research Risk May Impact Participation
9.09   p. 396	<input type="checkbox"/>	Ways in Which Patients Supplement Their Doctor's Efforts
9.10   p. 396	<input type="checkbox"/>	Race/Ethnicity
9.11   p. 397	<input type="checkbox"/>	Volunteer Education Levels
9.12   p. 397	<input type="checkbox"/>	"What Language do You Speak at Home?"

9.13   p. 398	<input type="checkbox"/>	How Many Studies Participated in
9.14   p. 398	<input type="checkbox"/>	Most Frequent Illness Addressed
9.15   p. 399	<input type="checkbox"/>	How Did You First Contact the Study Center?
9.16   p. 399	<input type="checkbox"/>	Promptness of Study Staff Reply
9.17   p. 400	<input type="checkbox"/>	How Long Was the Study?
9.18   p. 400	<input type="checkbox"/>	How Many Visits Were Required for the Study?
9.19   p. 401	<input type="checkbox"/>	Awareness of Clinical Trials Prior to Learning of the Study
9.20   p. 401	<input type="checkbox"/>	Factors Impacting Study Participation
9.21   p. 402	<input type="checkbox"/>	Factors Reducing Volunteer Willingness to Participate
9.22   p. 402	<input type="checkbox"/>	Deciding to Participate in Trials
9.23   p. 403	<input type="checkbox"/>	Study Participation Concerns
9.24   p. 403	<input type="checkbox"/>	Physicians' Ability to Guide Patients to Additional Information on Trials
9.25   p. 404	<input type="checkbox"/>	Compensation for Participation
9.26   p. 404	<input type="checkbox"/>	Patient Support
9.27   p. 405	<input type="checkbox"/>	Type of Support Received
9.28   p. 405	<input type="checkbox"/>	Initial Visit
9.29   p. 406	<input type="checkbox"/>	Informed Consent
9.30   p. 406	<input type="checkbox"/>	Did You Read the Informed Consent Form?
9.31   p. 407	<input type="checkbox"/>	Who Reviewed the Informed Consent Form with You?
9.32   p. 407	<input type="checkbox"/>	How Well Did You Understand the Informed Consent Form?
9.33   p. 408	<input type="checkbox"/>	"I Understood That I may Receive a Placebo (Sugar Pill) Instead of the Investigational Medicine"
9.34   p. 408	<input type="checkbox"/>	Understanding Study Expectations
9.35   p. 409	<input type="checkbox"/>	Understanding Study Expectations
9.36   p. 409	<input type="checkbox"/>	Understanding Study Expectations
9.37   p. 410	<input type="checkbox"/>	Volunteer Satisfaction With Efficacy of Care
9.38   p. 410	<input type="checkbox"/>	Dropping Out of the Study
9.39   p. 411	<input type="checkbox"/>	Reasons for Dropping out
9.40   p. 411	<input type="checkbox"/>	Volunteer Satisfaction with Quality of Care in Trials
9.41   p. 412	<input type="checkbox"/>	Volunteer Experiences
9.42   p. 412	<input type="checkbox"/>	Family Referrals
9.43   p. 413	<input type="checkbox"/>	Factors Impacting Participation in Pediatric Studies
9.44   p. 413	<input type="checkbox"/>	Projected Change in U.S. Population Mix: 2010-2050

- 9.45 | p. 414  Minority Participation in NIH Phase III Trials: Domestic Trials Funded by NIH, 2002-2006
- 9.46 | p. 414  Subgroup Representation in Clinical Trials
- 9.47 | p. 415  Minority Participation in Clinical Trials
- 9.48 | p. 415  Enrollment by Sex: 2003-2004
- 9.49 | p. 416  Protocols Exclusive to Sex: 2003-2004
- 9.50 | p. 416  How Interested are You in the Results of New Health Research Studies?
- 9.51 | p. 417  Which of the Following Reasons Did You Have for Not Participating?
- 9.52 | p. 417  How Did You Feel About Participating in this Health Research Study?
- 9.53 | p. 418  Opinions on Privacy Protection in Medical Studies
- 9.54 | p. 418  What Are the Main Reasons for Not Wanting to Give Advance General Consent or to Have Your Information Used Without a Consent?
- 9.55 | p. 419  "I Trust my Health Care Providers to Protect the Privacy of my Personal Medical Records"
- 9.56 | p. 419  "Health Researchers can Generally be Trusted to Protect the Privacy of Medical Records"
- 9.57 | p. 420  "The Privacy of Personal Medical Records is Not Well Protected Today by Laws and Practices"
- 9.58 | p. 420  "I Still Worry About a Professional Health Researcher Seeing my Medical Records"
- 9.59 | p. 421  Cancer Incidence by Race/ethnicity and Sex, 2004
- 9.60 | p. 421  Prostate Cancer by Race/ethnicity, 2004
- 9.61 | p. 422  Breast Cancer by Race/ethnicity, 2004
- 9.62 | p. 422  Cervical Cancer by Race/ethnicity, 2004
- 9.63 | p. 423  HIV/AIDS Distribution by Race/ethnicity, 1999-2003
- 9.64 | p. 423  Pancreatic Cancer Incidence by Race/ethnicity and Sex, 2004
- 9.65 | p. 424  Lung Cancer by Race/ethnicity and Sex, 2004
- 9.66 | p. 424  Diabetes Incidence by Race/ethnicity, 2001-2004
- 9.67 | p. 425  U.S. Population Without Health Insurance: 2004 and 2007
- 9.68 | p. 425  U.S. Population Without Health Insurance by Income Level, 2004 and 2007
- 9.69 | p. 426  Source of Prescription Drugs Expenditures: 1965-2015
- 9.70 | p. 426  Top Therapeutic Categories Contributing to Drug Expenditures: 2006

9.71   p. 427	□	Health Care Expenditure as a Percent of Income: 2004
9.72   p. 427	□	Health Care Expenditure by Age Group: 2004
9.73   p. 428	□	The Five Most Costly Conditions in the U.S.: 1997 and 2002
10.01   p. 438	□	Total NDA Submissions and Approvals, 2001-2007
10.02   p. 438	□	Total NDA Approvals, 2001-2008
10.03   p. 439	□	Total NME Approvals, 2001-2008
10.04   p. 439	□	NMEs and Domestic R&D Expenditure: 1999-2007
10.05   p. 440	□	NDA Approved by Review Status
10.06   p. 440	□	NDA Approvals by Chemical Type: 2002-2008
10.07   p. 441	□	2008 NDA Approvals by Chemical Type
10.08   p. 441	□	FDA Orphan Drug Approvals
10.09   p. 442	□	FDA Orphan Drug Designations
10.10   p. 442	□	FDA Orphan Drug Designations by Therapeutic Area, 2005
10.11   p. 443	□	FDA Orphan Drug Designations: Designations Granted by Therapeutic Area, 2000-2005
10.12   p. 443	□	Combination Products Assignments by Center FY2004-FY2007
10.13   p. 444	□	Combination Products Under Review: FY2004-FY2007
10.14   p. 444	□	New Biologic Approvals: 2002-2008
10.15   p. 445	□	Oncology NCE Launches per Year: 1997-2007
10.16   p. 445	□	NDA Approvals and Post-marketing Commitments: 2001-2008
10.17   p. 446	□	Status of Open Post-marketing Commitments: As of 2/4/09
10.18   p. 446	□	Percent of NCEs/NASs First Launched in U.S.: 1980-2004 by PDUFA Cohort
10.19   p. 447	□	Total Original IND Submissions: Commercial and Non-commercial
10.20   p. 447	□	IND Submissions: Original Commercial INDs by Year
10.21   p. 448	□	Generic Submissions and Approvals: 2001-2007
10.22   p. 448	□	Generic Drug Tentative Approvals: 1997-2007
10.23   p. 449	□	Generic Approval Times: Median Time to Approval, 1997-2007
10.24   p. 449	□	eCTD Submissions: Submissions as of Date
10.25   p. 450	□	First Action by FDA: All NDAs, Fiscal Year Cohorts
10.26   p. 450	□	First Action by FDA: Priority NDAs, Fiscal Year Cohorts
10.27   p. 451	□	First Action by FDA: Standard NDAs, Fiscal Year Cohorts

10.28   p. 451	□	FDA Fast Track Designations: Outcome of Fast Track Applications, 1998-2007
10.29   p. 452	□	FDA Fast Track Designations Granted by Therapeutic Area
10.30   p. 452	□	Accelerated NDA Review: NDAs Receiving Priority or Orphan Status 2002-2006
10.31   p. 453	□	Accelerated NME Review: NMEs Receiving Priority or Orphan Status, by Year
10.32   p. 453	□	Priority Review Status: Priority Review Designations by Therapeutic Area, 2004
10.33   p. 454	□	Priority NDA/BLA Approval Rates: Percentage Approved per Six-month Interval, by Year of Submission
10.34   p. 454	□	Standard NDA/BLA Approval Rates: Percentage Approved per six-month Interval, by Year of Submission
10.35   p. 455	□	Average Exclusivity for Newly Launched Drugs
10.36   p. 455	□	IDE Submissions: Total Submissions Received by Filing Type, 2001-2007
10.37   p. 456	□	IDE Decision Times: Average Time from Filing to Decision, 2001-2007
10.38   p. 456	□	HDE Applications: Total Submissions Received by Filing Type, 2001-2007
10.39   p. 457	□	510(k) Classifications: Submission Outcomes, FY2002-FY2007
10.40   p. 457	□	510(k) Submissions: Total Submissions Received, 2001-2007
10.41   p. 458	□	PMA Filings: Submission Outcomes, 2001-2007
10.42   p. 458	□	PMA Applications: Total Submissions Received by Filing Type, 2001-2007
10.43   p. 459	□	FDA Site Inspections: Site Inspections by Target, 2001-2007
10.44   p. 459	□	FDA Site Inspections: Site Inspections Worldwide by Outcome, 2002-2007
10.45   p. 460	□	FDA Site Inspections: Most Common Citations by Type, 2003-2007
10.46   p. 460	□	FDA Site Inspections: Common Citations by Type, 2003-2007
10.47   p. 461	□	FDA Site Inspections: Percent Site Inspections for Investigator Conduct, 1998-2007
10.48   p. 461	□	Resulting Actions from FDA Inspections: Data by Country, 2000-2008
10.49   p. 462	□	Resulting Actions from FDA Inspections: Data by Country, 2000-2008
10.50   p. 462	□	Resulting Actions from FDA Inspections: Data by Country, 2000-2008
10.51   p. 463	□	International Clinical Investigator Inspections: FY2002-2006
10.52   p. 463	□	Location of International Inspections: 1980-2006 (n=727)

- 10.53 | p. 464  Investigator Disqualifications: Number of Disqualifications from CDER/CBER, 1998-2008
- 10.54 | p. 464  Responsibility for Compliance Failure: Who Investigators Believe Is Responsible for Compliance Failure
- 10.55 | p. 465  FDA Public Health Advisories: Safety Warnings Issued for Approved Drugs, 2004
- 10.56 | p. 465  FDA Public Health Advisories: Safety Warnings Issued for Approved Drugs, 2005
- 10.57 | p. 466  FDA Public Health Advisories: Safety Warnings Issued for Approved Drugs, 2006
- 10.58 | p. 466  Approved Drugs Withdrawn from Market: 1980-2007
- 10.59 | p. 467  Adverse Event Reporting
- 10.60 | p. 467  FDA Biomonitoring Inspections with Site Visits: FY2000-FY2005
- 10.61 | p. 468  Process for FDA Review of Human Drug Applications: Total Costs
- 10.62 | p. 468  PDUFA Fees Collected
- 10.63 | p. 469  Top 10 Drug Classes Impacted by Medicare Part D
  
- 11.01 | p. 486  Ongoing Clinical Trials: Estimated Phase I Trials, 2008
- 11.02 | p. 486  Ongoing Clinical Trials: Estimated Phase II Trials, 2008
- 11.03 | p. 487  Ongoing Clinical Trials: Estimated Phase III Trials, 2008
- 11.04 | p. 487  Ongoing Clinical Trials: Estimated Phase IV Trials, 2008
- 11.05 | p. 488  World R&D Market Share: PhRMA-member Companies
- 11.06 | p. 488  Growth of Foreign-based Studies
- 11.07 | p. 489  Clinical Trial Initiations: Based on FDA-1572, 1990-2007
- 11.08 | p. 489  Sources of 1572 Filings: 2003-2007
- 11.09 | p. 490  Origin of Studies Initiated: 2003-2007
- 11.10 | p. 490  Clinical Trials by Origin: All U.S. INDs
- 11.11 | p. 491  Site Locations by Number of Countries Submitting 1572s
- 11.12 | p. 491  Selecting Countries for Multinational Trials: Key Criteria Used by Sponsors
- 11.13 | p. 492  1572s by Region: 2003-2007
- 11.14 | p. 492  1572s in Established Regions: 2003-2007
- 11.15 | p. 493  1572s Outside North America: 2003-2007
- 11.16 | p. 493  1572s in Ascending Markets: As a Percentage of All 1572 Filings, by Year

11.17   p. 494	□	1572s by Foreign Country: BRIC Countries, 2003-2007
11.18   p. 494	□	1572s by Foreign Country: BRIC Plus MK Countries, 2003-2007
11.19   p. 495	□	1572s by Ascending Region 2003-2007
11.20   p. 495	□	1572s by Foreign Country: Asia-Pacific Countries Part I, 2003-2007
11.21   p. 496	□	1572s by Region: Asia-Pacific Countries Part II, 2003-2007
11.22   p. 496	□	1572s by Top Five European Countries: 2003-2007
11.23   p. 497	□	U.S. INDs from Select Latin American Countries: 2003-2007
11.24   p. 497	□	Canadian Regulatory Review: NDSs Submitted and Approved, 2003-2007
11.25   p. 498	□	Canadian Regulatory Review: NASs Submitted and Approved, 2003-2007
11.26   p. 498	□	Canadian Regulatory Review: CTAs Submitted, 2001-2007
11.27   p. 499	□	Canadian Regulatory Review: CTAs Submitted by Phase, 2001-2007
11.28   p. 499	□	Canadian Regulatory Review: Priority Review Submissions Approved, 2003-2007
11.29   p. 500	□	Canadian Regulatory Review: Median Time to Approval for Priority and Standard NDSs, 2003-2007
11.30   p. 500	□	Canadian Regulatory Review: Median Time to Approval for Priority and Standard NASs, 2003-2007
11.31   p. 501	□	NIH Grants to Canada
11.32   p. 501	□	Large Market Potential in Asia-Pacific
11.33   p. 502	□	Japanese NDA Approvals: FY2002-2007
11.34   p. 502	□	Japanese Regulatory Review: Priority NDAs Approved
11.35   p. 503	□	Japanese Regulatory Review: NCEs Approved, 2001-2005
11.36   p. 503	□	New Drug Approvals in Japan: Conditional vs. Non-conditional
11.37   p. 504	□	New Drug Approvals in Japan: Conditional vs. Non-conditional Clinical Development Period
11.38   p. 504	□	Japanese Bridging Study Consultations
11.39   p. 505	□	Japanese Bridging Study Approvals
11.40   p. 505	□	Japanese Regulatory Review: Initial CTNs Submitted for new Chemical Entities (NCEs), 2001-2005
11.41   p. 506	□	Clinical Trial Notifications for Drugs: Japan
11.42   p. 506	□	Japanese vs. Overseas Approval: Years From Overseas Approval to Japanese Approval, new Drugs Approved in 2005
11.43   p. 507	□	Average Time From Initial Global Launch to Start of Marketing

11.44   p. 507	□	Japanese Approvals Accelerating: Time from NDA to Approval by Year of Submission, 1993-2003E
11.45   p. 508	□	Japanese Regulatory Review: New Medical Devices Approved, FY2002-2007
11.46   p. 508	□	Japanese Regulatory Review: Generic Approvals, FY2002-2007
11.47   p. 509	□	Japanese CROs: Number of Employees
11.48   p. 509	□	Japanese CROs: Employee Breakdown by Services
11.49   p. 510	□	Japanese CROs: Breakdown of Outsourced Projects by Services
11.50   p. 510	□	Japanese CROs: Employee Breakdown by Services
11.51   p. 511	□	NIH Grants to Japan
11.52   p. 511	□	Korean Trials
11.53   p. 512	□	Korean Trials: Drugs vs. Biologics
11.54   p. 512	□	Korean Trials: Biologic Trials, 2003-2007
11.55   p. 513	□	Clinical Trials in Taiwan: Local vs. Multinational
11.56   p. 513	□	Clinical Trials in Taiwan by Phase
11.57   p. 514	□	Singapore Regulatory Review: New Drug Approvals, 2001-2007
11.58   p. 514	□	Singapore Regulatory Review: Clinical Trials Initiated by Phase, 2003-2007
11.59   p. 515	□	Singapore Regulatory Review: Clinical Trials Initiated, 2007
11.60   p. 515	□	Singapore Biomedical Sciences Employment Growth
11.61   p. 516	□	Number of Clinical Trials in Hong Kong
11.62   p. 516	□	Australian Trials by Phase: FY2004/2005
11.63   p. 517	□	Australian Regulatory Review: Estimated Category 1 Applications, 2003/2004 - 2007/2008
11.64   p. 517	□	Australian Regulatory Review: Orphan Drug Designations Granted
11.65   p. 518	□	NIH Grants to Australia
11.66   p. 518	□	EU Regulatory Review: Outcomes for Centralized MAAs, 2003-2007
11.67   p. 519	□	EU Regulatory Review: MAAs Submitted Under the Centralized Procedure, 2003-2007
11.68   p. 519	□	EU Regulatory Review: Mutual Recognition Applications, 2003-2007
11.69   p. 520	□	EU Regulatory Review: Orphan Medical Product Designations, 2003-2007
11.70   p. 520	□	EU Regulatory Review: Orphan Designation Review Time, 2003-2007
11.71   p. 521	□	EU Regulatory Review: Orphan Designations, 2003-2007

11.72   p. 521	□	EU Regulatory Review: Mean Centralized MAA Review Times, 2003-2007
11.73   p. 522	□	NIH Grants to EU Members: 2000-2008
11.74   p. 522	□	Clinical Trials Approved in Russia
11.75   p. 523	□	Percentage of Clinical Trials Conducted by CROs in Russia
11.76   p. 523	□	Russian Patients Enrolled in Clinical Trials
11.77   p. 524	□	Originating Country of International Clinical Trials in Russia
11.78   p. 524	□	Active Phase II-IV Sites: East Europe/Russia
11.79   p. 525	□	Registered Trials: Emerging Cities
11.80   p. 525	□	Major Barriers to Expansion of the Polish Clinical Trials Market
11.81   p. 526	□	Indian Investigators Filing 1572s
11.82   p. 526	□	NIH Grants to India
11.83   p. 527	□	Projected Indian Pharmaceutical Market: 2004-2009
11.84   p. 527	□	The Indian Clinical Trials Market: an Overview
11.85   p. 528	□	Healthcare Coverage in India by Source
11.86   p. 528	□	Indian Pharmaceutical Market by Therapeutic Area
11.87   p. 529	□	Latin American Demographics
11.88   p. 529	□	Population Distribution by Age: World and Select Latin American Countries
11.89   p. 530	□	Latin American Populations: Five Largest Countries
11.90   p. 530	□	Argentine Clinical Trial Protocols Approved: 1994-2006
11.91   p. 531	□	Trial Sponsors in Argentina: 1994-2006
11.92   p. 531	□	Argentine Trials by Phase: 1994-2006
11.93   p. 532	□	South African Healthcare Market
11.94   p. 532	□	Estimated Pharmaceutical Use in China: 2000-2010
11.95   p. 533	□	NIH Grants to Foreign Countries: Grants to All Research Interests, 2000-2008
11.96   p. 533	□	International NIH Grant Recipients: Top Recipients by Country, 2008
11.97   p. 534	□	AT Kearney Overall Country Attractiveness Index for Clinical Trials
11.98   p. 534	□	International Regulatory Bodies: Selected Regulatory Bodies and Filing Names
11.99   p. 535	□	Regulatory Bodies for Selected EU Countries
11.100   p. 535	□	Drug Spending as a Percentage of Total Health Spending: 1980-2006

- 11.101 | p. 536 □ Percent of GDP Spent on Health Care: Select Countries, 1980-2006
- 11.102 | p. 536 □ Source of Prescription Drugs Expenditures: 1965-2004
- 11.103 | p. 537 □ Public vs. Private Spend on Healthcare: Asia-Pacific